
Remedium Bio
Founded Year
2020Stage
Seed VC | AliveTotal Raised
$3.67MLast Raised
$2.3M | 10 mos agoRemedium Bio's Product Videos


Compete with Remedium Bio?
Ensure that your company and products are accurately represented on our platform.
Remedium Bio's Products & Differentiators
RMD 1101
First-in-class potentially disease modifying treatment for Osteoarthritis.
Expert Collections containing Remedium Bio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Remedium Bio is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Remedium Bio Patents
Remedium Bio has filed 1 patent.
The 3 most popular patent topics include:
- Clusters of differentiation
- Death
- Medical aspects of death

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/20/2022 | Application |
Application Date | 5/20/2022 |
---|---|
Grant Date | |
Title | |
Related Topics | |
Status | Application |
Latest Remedium Bio News
Mar 30, 2023
Product Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed on a collaboration for AAV drug development. The agreement covers Remediums lead candidate, a first-in-class disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remediums lead candidate in Biovians AAV manufacturing platform development program. Biovians second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L and utilizing chromatography for standard purification. Biovian has invented a robust way to efficiently separate full capsids from empty capsids, applicable to large-scale manufacturing. Antti Nieminen, CEO at Biovian: "We are pleased to start a collaboration with Remedium Bio and to include Remediums AAV candidate in our ongoing second-generation AAV platform development program. Remediums therapeutic candidate will be important in the validation of Biovians second generation AAV platform bringing a new level of quality and efficiency to the viral vector manufacturing space. Frank Luppino, President and CEO at Remedium Bio: Having recently generated one of the most comprehensive preclinical efficacy datasets in Osteoarthritis and presented at the 2023 Orthopedic Research Society meeting, we are extremely excited to scale production of our lead candidate RMD 1101 to support Toxicology and Clinical demand. Partnering with Biovians high-productivity viral vector manufacturing process will enable clinical supply and cost-effective production at eventual commercial scale for a disease that impacts hundreds of millions of people around the globe. About Remedium Bio Remedium Bio, Inc., is a Boston area biotechnology company focused on the development of curative therapies for a broad range of pathologies. The company is founded on the vision of changing lives via curative breakthroughs, grounded in combining proven scientific fundamentals in novel ways, to treat well-characterized pathologies. Remediums current lead candidate is a disease-modifying treatment for Osteoarthritis that is based on the clinically validated mechanism of FGF18. Remediums scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues. Remediums pipeline includes gene therapy treatments in the fields of Rheumatology, Endocrinology, Neurology, and Immunology. Additional information is available at https://www.remedium-bio.com/. About Biovian Biovian is a Contract Development and Manufacturing Organization, CDMO that provides premium services to biotech companies developing innovative gene therapies and biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on viral vector production and microbial production of recombinant proteins and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at https://biovian.com/. Press Contact: taru.varri@biovian.com
Remedium Bio Frequently Asked Questions (FAQ)
When was Remedium Bio founded?
Remedium Bio was founded in 2020.
Where is Remedium Bio's headquarters?
Remedium Bio's headquarters is located at 1116 Great Plain Avenue, Needham.
What is Remedium Bio's latest funding round?
Remedium Bio's latest funding round is Seed VC.
How much did Remedium Bio raise?
Remedium Bio raised a total of $3.67M.
Who are the investors of Remedium Bio?
Investors of Remedium Bio include Sherwood Ventures, Angel Star Ventures, APIS Health Angels, Guindy Alumni Angels, MicroVentures Marketplace and 4 more.
Who are Remedium Bio's competitors?
Competitors of Remedium Bio include Pacira Biosciences and 1 more.
What products does Remedium Bio offer?
Remedium Bio's products include RMD 1101 and 3 more.
Compare Remedium Bio to Competitors
Lilly is a pharmaceutical company. The company focuses on diabetes, cancer, immunology, pain, and neurodegeneration drugs. It is based in Toronto, Ontario.
utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.�MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.
EZRA Innovations currently holds exclusive worldwide rights in a controlled-release drug delivery system. Drug Surfactant Complex (DSC) Deoxycholate is used in combination with active pharmaceutical ingredients (API), DSC possesses the ability to change the chemical moiety of existing drugs and better extend release rates.
Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.
Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.
Medipacs develops a non-mechanical infusion pump using a expandable polymer. TheMedipacs pump is designed to be wearable, programmable and disposable to allow for greater accuracy, patient comfort and convenience at a lower cost. The Medipacs novel polymer technology enables drug infusion pumps that are wearable, programmable and disposable to allow for greater accuracy, patient comfort and convenience at a lower cost.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.